Drug intelligence / Profile preview

Tertinat

Development stage: Phase 2
Administration: Oral

Overview

Tertinat is a biologically active food supplement currently being evaluated in clinical trials for its potential to influence the progression of atherosclerosis and improve treatment outcomes for cardiovascular diseases. It is also being studied for its ability to prevent pro-atherogenic modification of lipoproteins and to impact inflammatory activity. Tertinat is administered orally alongside standard patient therapy.

Beyond the preview

Go deeper on Tertinat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tertinat.

Explore the full profile